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Abstract
 
Several immune-based approaches are being considered for modulation of inflammatory T cells
and amelioration of autoimmune diseases. The most recent strategies include simulation of pe-
ripheral self-tolerance by injection of adjuvant free antigen, local delivery of cytokines by ge-
netically altered T cells, and interference with the function of costimulatory molecules. Al-
though promising results have been obtained from these studies that define mechanisms of T
cell modulation, efficacy, practicality, and toxicity, concerns remain unsolved, thereby justify-
ing further investigations to define alternatives for effective downregulation of aggressive T
cells. In prior studies, we demonstrated that an immunoglobulin (Ig) chimera carrying the en-
cephalitogenic proteolipid protein (PLP)1 peptide corresponding to amino acid sequence 139–
 
151 of PLP, Ig-PLP1, is presented to T cells 
 
z
 
100-fold better than free PLP1. Here, we dem-
onstrate that aggregation endows Ig-PLP1 with an additional feature, namely, induction of
interleukin (IL)-10 production by macrophages and dendritic cells, both of which are antigen-
presenting cells (APCs). These functions synergize in vivo and drive effective modulation of
autoimmunity. Indeed, it is shown that animals with ongoing active experimental allergic en-
cephalomyelitis dramatically reduce the severity of their paralysis when treated with adjuvant
free aggregated Ig-PLP1. Moreover, IL-10 displays bystander antagonism on unrelated autore-
active T cells, allowing for reversal of disease involving multiple epitopes. Therefore, aggre-
gated Ig-PLP1 likely brings together a peripheral T cell tolerance mechanism emanating from
peptide presentation by APCs expressing suboptimal costimulatory molecules and IL-10 by-
stander suppression to drive a dual-modal T cell modulation system effective for reversal of au-
toimmunity involving several epitopes and diverse T cell specificities.
Key words: autoimmunity • antigen delivery • bystander downregulation • cytokine 
antagonism • T cell modulation
 
Introduction
 
During development, T cells whose antigen receptors are
devoid of self-reactivity exit the thymus and participate in
immune surveillance, whereas those bearing receptors en-
dowed with self-reactivity are negatively selected and de-
leted by programmed cell death (1). This process of T cell
screening and selection, known as central tolerance, re-
quires the antigen to be available in the thymus in sufficient
quantities and in a form presentable by MHC molecules
(2–5). Although central tolerance exerts a tight control on
the shaping of the T cell repertoire, some self-reactive T
cells still escape the thymus and migrate to the periphery
(6–8). If the antigen is available in the periphery, a second
round of T cell screening, known as peripheral tolerance,
will follow to further minimize autoreactivity (3, 9–13).
Presumably, peripheral tolerance develops as a consequence
of presentation of autoantigen by nonactivated APCs ex-
pressing minimal or no costimulatory molecules (3, 14).
For sequestered autoantigens that are not available for
presentation in either the thymus or the periphery, the cor-
responding T cells will circulate harmlessly. However,
events that trigger exposure of those autoantigens, which
are usually accompanied by conditions favorable for activa-
tion of local APCs, lead to an optimal presentation to and
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activation of the circulating T cells (15–18). The results of
this T cell activation may be the escalation of inflammatory
reactions and injury of specific tissues and organs (19–21).
Supply of antigen in an adjuvant free form might not
stimulate the expression of costimulatory molecules on
APCs and thereby drive an antigen presentation inadequate
for T cell activation (3, 22, 23). Prior studies have in fact
indicated that this approach modulates autoreactive T cells
and promotes recovery from illness (24–26). However, the
usefulness of this approach for modulation of autoimmu-
nity is hampered by the unlimited availability of autoanti-
gen at the injury site and the consequent continuous acti-
vation of the self-reactive T cells. In addition, as bystander
suppression is unlikely to occur, the approach holds little
promise for modulation of T cell–mediated autoimmunity
involving multiple antigens. To overcome these issues, an
in vitro approach that uses plasmid (27) and viral (28, 29)
vector-driven modulatory cytokines was adopted. Indeed,
autoreactive T cell clones or hybridomas expressing the cy-
tokine IL-4 or IL-10, as a consequence of transfection or
infection, induced recovery from disease when injected
into animals with ongoing experimental autoimmune en-
cephalomyelitis (EAE)
 
1
 
 (27, 28). This is a promising ap-
proach and bodes well for the development of practical
strategies that could combine both peripheral tolerance and
cytokine antagonism to combat autoimmunity.
It has previously been shown that peptide delivery on Igs
increases presentation by 100–1,000-fold relative to free
peptide (30, 31). It is also known that cross-linking of Fc
receptors (FcRs) on target cells by antigen–antibody com-
plexes can trigger the production of cytokines (32–34).
Moreover, aggregation of Igs confers the effector functions
associated with the Fc fragment without the need for com-
plex formation (35, 36). Here, the encephalitogenic pro-
teolipid protein (PLP)1 was genetically engineered into an
Ig molecule (30), and the resulting Ig-PLP1 chimera was
aggregated and assayed for modulation of autoreactive T
cells and amelioration of active EAE. The results show that
aggregated (agg) Ig-PLP1 induced IL-10 secretion by both
macrophages and dendritic cells (DCs) but not B cells. In
vitro, APCs incubated with agg Ig-PLP1 presented PLP1
to specific T cells. However, because of the IL-10 secreted
by the presenting APCs, IFN-
 
g
 
 production by the T cells
was impaired. In vivo, when soluble (sol) Ig-PLP1 was in-
jected into mice with ongoing EAE, the severity of disease
was slightly reduced. However, when mice were given agg
Ig-PLP1, full recovery was achieved. Moreover, agg Ig-
PLP1 was able to modulate disease induced by either an
encephalitogenic peptide other than PLP1 or by a central
nervous system (CNS) homogenate. Neutralization of en-
dogenous IL-10 by injection of anti–IL-10 antibody during
administration of agg Ig-PLP1 restored disease severity.
Therefore, agg Ig-PLP1 triggers IL-10 production by
 
APCs, drives inadequate peripheral presentation of PLP1,
and couples both events to modulate autoimmunity in-
volving diverse T cell specificities.
 
Materials and Methods
 
Animals.
 
SJL/J (H-2
 
S
 
) mice were purchased from Harlan,
bred, and maintained in our animal care facility for the duration
of the experiments.
 
Antigens
 
Peptides. 
 
The peptides used in this study were purchased
from Research Genetics, and were HPLC purified to 
 
.
 
90% pu-
rity. PLP1 peptide (HSLGKWLGHPDKF) encompasses amino
acid (aa) residues 139–151 of PLP and is encephalitogenic in SJL/J
mice (37). PLP2 peptide (NTWTTCQSIAFPSK), encompassing
aa 178–191 of PLP, is likewise encephalitogenic in SJL/J (38).
Myelin basic protein (MBP)-3 peptide (VHFFKNIVTPRTP)
corresponding to aa residues 87–99 of MBP is also I-A
 
S
 
 restricted,
and induces EAE in SJL/J mice (39). Hemagglutinin (HA) pep-
tide, an I-E
 
d
 
–restricted epitope (31), corresponding to aa residues
110–120 of HA, was used for negative control purposes.
 
CNS Homogenate.
 
50 frozen unstripped rat brains (Pelfreez
Biologicals) were homogenized in PBS using a Waring blender
and adjusted to 300 mg/ml with PBS. CNS homogenate was
stored at 
 
2
 
20
 
8
 
C.
 
Ig-PLP Chimeras. 
 
The Ig-PLP1 and Ig-PLP2 chimeras har-
bor, within the heavy chain CDR3 region, PLP1 and PLP2, re-
spectively, and have been described previously (30, 40, 41). Ig-W
is the parental IgG2b antiarsonate antibody, 91A3, not encom-
passing any PLP peptide, and has been described elsewhere (30).
Large-scale cultures of Ig-W, Ig-PLP1, and Ig-PLP2 transfectants
were performed in DMEM containing 10% serum supreme (Bio-
Whittaker) and purified on separate rat anti–mouse 
 
k
 
 chain
sepharose columns to avoid cross-contamination. Subsequently,
the Ig chimeras were dialyzed against PBS and concentrated on
collodion membranes (Schleicher & Schuell). The chimeras were
aggregated by precipitation with 50% saturated (NH
 
4
 
)
 
2
 
SO
 
4
 
 as de-
scribed (42). In brief, filtered 100% saturated (NH
 
4
 
)
 
2
 
SO
 
4
 
 was
added at an equal volume to the sol Ig chimera preparation. The
mixture was incubated at 24
 
8
 
C for 1 h with gentle agitation every
20 min. Subsequently, the samples were spun down at 10,000
rpm, and the pellet was resuspended at 1 mg/ml in PBS. Electro-
phoresis on a 10% acrylamide gel indicated that the sol Ig chimera
entered the gel and migrated 
 
z
 
160 kD. However, the agg Ig chi-
mera did not enter the gel. Knowing that we applied the equiva-
lent of 2 
 
m
 
g of agg Ig chimera, and that the sensitivity of the
technology is 0.1 
 
m
 
g, we concluded that at least 95% of the agg
Ig chimera preparation is in an aggregate form.
 
Induction of EAE
 
6–8-wk-old mice were induced for EAE by subcutaneous in-
jection in the footpads, and at the base of the limbs and tail with a
200 
 
m
 
l IFA/PBS (vol/vol) solution containing the autoantigen
and 200 
 
m
 
g 
 
Mycobacterium tuberculosis
 
 H37Ra. 6 h later, the mice
were given intravenous 5 
 
3
 
 10
 
9
 
 inactivated 
 
Bordetella pertussis
 
(Bioport). A second injection of 
 
B. pertussis
 
 was given after 48 h.
Subsequently, the mice were scored daily for clinical signs of
EAE as follows: 0, no clinical score; 1, loss of tail tone; 2, hind-
limb weakness; 3, hindlimb paralysis; 4, forelimb paralysis; and 5,
moribund or death. In some experiments, purified pertussis toxin
 
1
 
Abbreviations used in this paper:
 
 agg, aggregated; aa, amino acid; CNS,
central nervous system; DC, dendritic cell; EAE, experimental autoim-
mune encephalomyelitis; HA, hemagglutinin; MBP, myelin basic pro-
tein; PLP, proteolipid protein; sol, soluble. 
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Legge et al.
(List Biological Laboratories, Inc.) was used instead of whole 
 
B.
pertussis
 
 organism.
 
Treatment of EAE with Ig-PLP1
 
Mice induced for EAE with PLP1, PLP2, a mixture of PLP1
plus PLP2, or CNS homogenate began receiving treatment with
Ig-PLP1 after loss of tail tone, which occurs regularly between
days 6 and 8 after disease induction. Treatment injections were
given intraperitoneally in PBS on days 9, 13, and 17.
 
Histopathology
 
Mice treated with agg Ig-PLP1 or agg Ig-W were killed at the
peak of the initial phase of disease (day 28 after disease induction),
and the brain and spinal cord were removed, fixed with formalin,
and embedded in paraffin. Serial cross-sections (6 
 
m
 
m) from the
cerebellum, cerebrum, and lumbar cord were cut and stained
with hematoxylin and eosin. Perivascular clusters containing at
least 20 mononuclear cells were counted as inflammatory foci.
 
T Cells
 
TCC-PLP1-1B10. 
 
Adult SJL mice were immunized subcu-
taneously with 100 
 
m
 
g PLP1 peptide in CFA, and 10 d later the
draining LNs were removed and the cells (5 
 
3
 
 10
 
6
 
 cells/ml) were
stimulated with PLP1 (15 
 
m
 
g/ml). After 5 d, the blasts were sepa-
rated on a Histopaque gradient (Sigma-Aldrich), and then restim-
ulated with peptide and fresh irradiated (3,000 rads) syngeneic
APCs. 10 d later, the cells were washed, resuspended in media
containing 10% T-Stim (Collaborative Research), and rested for
7 d. After three cycles of stimulation/resting, the cells were
cloned by limiting dilution (1 cell/3 wells) and positives were
subjected to a second round of limiting dilution cloning. Subse-
quently, one clone, designated TCC-PLP1-1B10, was selected
for these studies.
 
Isolation of Macrophages, DCs, and B Cells
 
Macrophages. 
 
Macrophages were obtained from the perito-
neal cells of mice injected with thioglycollate broth as described
previously (43). In brief, 2 ml of thioglycollate broth was injected
intraperitoneally, and after 5 d the macrophages were removed by
washing the peritoneal cavity with 8 ml of HBSS, 4 
 
m
 
M EDTA.
Macrophage purity was 
 
$
 
93% as determined by FACS
 
®
 
 analysis
using antibody to F4/80 marker.
 
DCs. 
 
DCs were purified from SJL/J spleen according to the
standard collagenase/differential adherence method (44). Cell pu-
rity was 
 
$
 
94% as determined by FACS
 
®
 
 analysis using antibody
to the 33D1 marker.
 
B Cells. 
 
SJL/J splenocytes were panned on plates coated
with rat anti–mouse 
 
k
 
 (1 mg/ml) for 15 min at 25
 
8
 
C. Nonadher-
ent cells were washed out with PBS. B cells were then dissociated
from the plate by incubation with lidocaine HCl (0.8 mg/ml),
followed by vigorous pipetting. Cell purity was 
 
$
 
90% as deter-
mined by FACS
 
®
 
 analysis for expression of B220 marker.
 
Proliferation Assays.
 
SJL/J splenocytes (10 
 
3
 
 10
 
5
 
 cells/well/
100 
 
m
 
l) were pulsed with graded amounts of antigen on round-
bottomed 96-well plates for 4 h, pelleted, fixed with 1%
paraformaldehyde for 15 min, washed, and transferred to a fresh
96-well plate. TCC-PLP1-1B10 cells (0.5 
 
3
 
 10
 
5
 
 cells/well/100
 
m
 
l) were then added and incubated for 3 d. Subsequently, 1 
 
m
 
Ci
[
 
3
 
H]thymidine was added per well, and the incubation continued
for an additional 14.5 h. The cells were then harvested on glass fi-
ber filters, and incorporated [
 
3
 
H]thymidine was counted using an
Innotech 
 
b
 
 counter (Wohlen).
 
Cytokine Detection
 
ELISA. 
 
ELISA was done according to BD PharMingen’s
standard protocol. The capture antibodies were rat anti–mouse
IL-2, JES6-1A12; rat anti–mouse IL-4, 11B11; rat anti–mouse
IFN-
 
g
 
, R4-6A2; rat anti–mouse IL-10, JES5-2A5; and rat anti–
mouse IL-5, TRFK5. The biotinylated anticytokine antibodies
were rat anti–mouse IL-2, JES6-5H4; rat anti–mouse IL-4,
BVD6-24G2; rat anti–mouse IFN-
 
g
 
, XMG1.2; rat anti–mouse
IL-10, JES5-16E3; and rat anti–mouse IL-5, TRFK4. ELISA for
the detection of active TGF-
 
b
 
 was preformed using the human
TGF-
 
b
 
1 DuoSet kit (Genzyme) according to the manufacturer’s
instructions. Bound ligand was revealed using the TMB micro-
well peroxidase substrate system (Kirkegaard & Perry Laborato-
ries). Assays were read on a SpectraMAX 340 counter (Molecular
Devices). Graded amounts of recombinant mouse IL-2, IL-4,
IFN-
 
g
 
, IL-10, IL-5, and TGF-
 
b
 
 were included in all experiments
for construction of standard curves. The cytokine concentration
in culture supernatants was estimated by extrapolation from the
linear portion of the standard curve.
 
Enzyme-linked Immunospot. 
 
Enzyme-linked immunospot (ELI-
SPOT) assays were used to measure the cytokines produced by
LN T cells upon stimulation with antigen as described (41). In
brief, LN cells (5 
 
3
 
 10
 
5
 
 cells/100 
 
m
 
l/well) and the antigen (100
 
m
 
l/well) were incubated in HA-multiscreen plates (Millipore)
coated with capture antibody for 24 h. Bound cytokines were re-
vealed with peroxidase and anticytokine antibodies. The anticy-
tokine antibody pairs used here were those described for the
ELISA technique. Spots were counted under a dissecting micro-
scope.
 
Stimulation of Cytokine Production by TCC-PLP1-1B10
 
Stimulation was performed with both irradiated and fixed
APCs. In one case, SJL/J splenocytes were irradiated (3,000 rads)
and plated (at 5 
 
3
 
 10
 
5
 
 cells/well/50 
 
m
 
l) with graded concentra-
tions of antigens (100 
 
m
 
l/well). After 1 h, TCC-PLP1-1B10 cells
(0.5 
 
3
 
 10
 
5 
 
cells/well/50 
 
m
 
l) were added and the culture was in-
cubated for 24 h. For fixed APCs, SJL/J splenocytes (10 
 
3
 
 10
 
5
 
cells/well/100 
 
m
 
l) were pulsed with graded amounts of antigen,
fixed with 1% paraformaldehyde, and incubated with TCC-
PLP1-1B10 cells (0.5 
 
3
 
 10
 
5
 
 cells/well/100 
 
m
 
l) for 24 h. Detec-
tion and quantification of cytokines were then assessed by ELISA
from 100 
 
m
 
l of culture supernatant.
 
Results
 
Soluble Ig-PLP1 Reduces Paralytic Severity and Suppresses
Clinical Relapses in Mice with Ongoing EAE.
 
Prevention
and treatment of active autoimmune disease have been
achieved by injection of adjuvant-free autoantigens or pep-
tides (24–26, 45–49). However, repetitive injections of the
autoantigens are required, and the disease rebounds when
the supply of antigen is discontinued (48). One approach
that may overcome these setbacks and modulate active dis-
ease is the delivery of the self-peptide on Igs. Igs have long
half-lives and grant the peptides access to newly synthesized
MHC molecules (31, 50), which could lead to efficient
peptide loading onto MHC molecules (50) over an ex-
tended period of time. To test the Ig delivery system for
treatment of active autoimmunity, SJL/J mice were in-
duced for EAE with free PLP1 peptide, and when the clin-
ical signs of disease became apparent the animals were 
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given three injections of sol Ig-PLP1 in saline at 4-d inter-
vals and assessed for reduction in disease severity. Control
mice were given sol Ig-W, the parental Ig without any
PLP1 peptide. The results illustrated in Fig. 1 show that
mice treated with the sol Ig-W had an initial severe phase
of paralysis with a mean maximal score of 3.7 
 
6
 
 0.5 and
displayed relapses throughout the 120-d period of exami-
nation. The mice treated with sol Ig-PLP1, however, had a
reduced severity of paralysis at the initial phase of disease
with a mean maximal score of 2.5 
 
6
 
 0.3 (
 
P
 
 
 
,
 
 0.005) and
fully recovered by day 42. Mice treated with 10-fold excess
of free PLP1 peptide had a slight reduction in the severity
of paralysis at the initial phase of disease (mean maximal
clinical score 3.0 
 
6
 
 0.2), but never recovered and under-
went relapses throughout the entire 120-d observation pe-
riod (Fig. 1).
 
Aggregated Ig-PLP1 Displays Higher Efficacy Than Soluble
Ig-PLP1 in Reversing Active EAE.
 
Binding of antigen–anti-
body complexes to FcRs on target cells induces the pro-
duction of cytokines (34, 51, 52). IL-10, produced by mac-
rophages upon exposure to antigen–antibody complexes,
exerts antagonist effects on IL-12 production and reverses
proinflammatory responses (34, 52). Similar to complex-
ation of antibodies with antigen, aggregation confers to Igs
the effector functions associated with the Fc fragment (35,
36). These include the binding of complement and cross-
linking of FcRs. We then reasoned that aggregation of Ig-
PLP1 should be able to cross-link FcRs on APCs and drive
both cytokine production and efficient loading of PLP1
peptide onto MHC molecules. If this hypothesis proved
accurate and IL-10 was among the cytokines produced by
APCs, agg Ig-PLP1 should be much more efficient than sol
Ig-PLP1 for modulation of active EAE. To investigate this
issue, mice were induced for EAE with free PLP1 peptide
and when signs of clinical EAE became apparent, they
were given three injections of 300 
 
m
 
g agg Ig-PLP1 at 4-d
intervals and assessed for signs of paralysis. Control mice
were treated with agg Ig-W instead of agg Ig-PLP1. As can
be seen in Fig. 2 a, the initial phase of paralytic disease se-
verity was reduced from a mean maximum score of 3.3 
 
6
 
0.3 in agg Ig-W–treated animals to 1.1 
 
6
 
 0.5 (
 
P
 
 
 
, 
 
0.001)
in the agg Ig-PLP1 recipient mice. In addition, the animals
fully recovered within 9 d of completion of the treatment
and never relapsed throughout the entire 120-d observa-
tion period, whereas agg Ig-W–treated mice never recov-
ered and showed relapses throughout the entire period of
clinical assessment. The effectiveness of agg Ig-PLP1 is also
apparent when the paralytic clinical signs of agg Ig-PLP1–
treated animals were compared with those of animals in-
jected with sol Ig-PLP1 (
 
P
 
 
 
,
 
 0.001) (Fig. 2 b). Indeed, the
mean maximum clinical score was much lower and the re-
covery was faster. Histologic examination of the cerebel-
lum at the peak of disease indicated a lower number of foci
Figure 1. Inhibition of paralytic relapses by treatment with sol Ig-
PLP1. Groups of 6–8-wk-old SJL/J mice were induced for EAE with 100
mg PLP1 peptide, and then treated intraperitoneally with 500 mg sol Ig-
PLP1, 500 mg sol Ig-W, or 100 mg free PLP1 peptide in PBS on days 9,
13, and 17 after disease induction. Each point represents the mean clinical
score of eight mice. These results are representative of two independent
experiments. On the basis of 150-kD molecular mass for Ig-PLP1 and
1.5-kD molecular mass for free PLP1, we estimated that the 300 mg free
PLP1 given during the three injections correspond to z200 nmol of PLP1
peptide, and the 1,500 mg sol Ig-PLP1 encompasses z20 nmol PLP1
peptide. Therefore, when free PLP1 is used for treatment the mice were
given z10-fold more peptide than for treatment with sol Ig-PLP1.
Figure 2. Effective amelioration of EAE by agg Ig-PLP1. (a) Groups of
mice (eight per group) were induced for EAE with 100 mg PLP1 and
then treated with 300 mg of agg Ig-PLP1 or agg Ig-W in PBS on days 9,
13, and 17 after disease induction. (b) Direct comparison of the disease
course of PLP1 peptide induced EAE after treatment with sol Ig-PLP1
(from Fig. 1) versus agg Ig-PLP1 (from 2 a). Each point represents the
mean clinical score of eight mice. These results are representative of three
independent experiments. The 900 mg agg Ig-PLP1 given to mice con-
tains z12 nmol PLP1. This amount is z17-fold lower than the 200 nmol
given as free PLP1, yet disease modulation was much more effective.2043 Legge et al.
and a reduced number of infiltrating mononuclear cells per
foci in the mice treated with agg Ig-PLP1 versus those
given agg Ig-W (Fig. 3). Moreover, when serial histologic
cross-sections were prepared from both the brain and spinal
cord and the mean foci per cross section were estimated,
there was a two- to threefold reduction in the number of
foci in agg Ig-PLP1–treated mice versus mice recipient of
agg Ig-W (Table I). Furthermore, the foci in agg Ig-PLP1–
treated mice had fewer infiltrating mononuclear cells than
those of agg Ig-W–treated mice (agg Ig-W, 73 6 39; agg
Ig-PLP1: 32 6 14, P , 0.005).
Aggregated Ig-PLP1 Induces the Production of IL-10 by
APCs and Downregulates IFN-g Secretion by Specific T Cells In
Vitro. To delineate the mechanism underlying the effec-
tive modulation of EAE by agg Ig-PLP1, we sought to in-
vestigate whether agg Ig-PLP1 stimulates the production of
IL-10 by APCs, and whether such IL-10 would display an
inhibitory function on T cells engaged in the recognition
of the PLP1 peptide presented by IL-10–producing APCs.
To this end, naive splenocytes were incubated with sol or
agg Ig chimeras, and the supernatants were used for IL-10
detection. As indicated in Fig. 4 a, agg Ig-PLP1, Ig-PLP2,
and Ig-W chimeras stimulated the production of IL-10 by
splenic cells in a dose-dependent manner. The soluble
forms of the chimeras did not induce detectable levels of
IL-10. Furthermore, we decided to investigate whether
cells known to function as professional APCs are able to
produce IL-10 upon incubation with agg Ig chimeras. To
address this issue, thioglycollate-induced peritoneal mac-
rophages and splenic B and DCs were isolated and tested
for IL-10 production upon incubation with agg Ig-PLP1.
Fig. 4 b indicates that macrophages and DCs, but not B
cells, produce IL-10 upon incubation with agg Ig-PLP1.
Mouse IgM was unable to stimulate IL-10 production by
any of the APCs tested. These results indicate that agg Ig-
PLP1 cross-links FcgR and induces the production of IL-
10 by APCs. Furthermore, preincubation of APCs with
soluble mouse IgG inhibited agg Ig-PLP1–induced IL-10
production (data not shown). These results indicate that the
IL-10 produced by the APCs was due to cross-linking of
FcgR rather than to contamination with endotoxin.
To investigate the effect that APC-derived IL-10 might
have on T cells specifically engaged with the APCs through
antigen presentation, a PLP1-specific Th0 clone able to
produce both type I and type II cytokines upon peptide
stimulation was used. This clone, designated TCC-PLP1-
1B10, proliferates upon incubation with paraformalde-
hyde-fixed splenic APCs that were previously pulsed with
free PLP1 peptide or agg Ig-PLP1 (Fig. 5 a). TCC-PLP1-
1B10 did not show significant proliferation when the APCs
were pulsed with the negative control PLP2 or agg Ig-
PLP2. When tested for cytokine production upon incuba-
tion with nonfixed splenic APCs and free PLP1 peptide,
TCC-PLP1-1B10 produced significant amounts of IL-2,
IL-4, and IFN-g (Fig. 5, b–d). All three cytokines were
also detected when agg Ig-PLP1 was used for stimulation
(Fig. 5, b–d). However, IL-10 was detectable at significant
levels when the stimulator was agg Ig-PLP1 but not free
PLP1 (Fig. 5 e). As agg Ig-PLP1 induces IL-10 production
by macrophages and DCs, it is likely that the IL-10 seen in
the T cell cytokine assessment assay was the product of
Figure 3. Agg Ig-PLP1 signif-
icantly reduces the number of in-
flammatory foci within the CNS.
Serial cross-sections were pre-
pared at the peak of disease (day
28) from the cerebellum of mice
treated with agg Ig-W (a) and
agg Ig-PLP1 (b) and described in
the legend to Fig. 2. The brains
were fixed with formalin, em-
bedded in paraffin, and stained
with hematoxylin and eosin as
described in Materials and Meth-
ods. Magnifications: 340.
Table I. Treatment with Agg Ig-PLP1 Ablates Clinical and Histologic EAE
Histologic EAE:
foci/cross-section
Treatment
Clinical EAE:
mean maximum severity Cerebrum Lumbar spinal cord
Agg Ig-W 3.3 6 0.3 11.7 6 2.1 18.5 6 3.3
(P , 0.001) (P , 0.001) (P , 0.001)
Agg Ig-PLP1 1.1 6 0.5 6.5 6 0.5 6.9 6 1.1
6–8-wk-old mice were induced for EAE with PLP1 as described in Materials and Methods, and then treated with 300 mg agg Ig-PLP1 or agg Ig-W
on days 9, 13, and 17 after disease induction and scored daily for clinical disease. The mean maximum severity was determined by averaging the
maximal clinical score obtained from each mouse within a group. To determine histological disease, brains and spinal cords were removed from mice
on day 28 after disease induction (peak of disease), fixed in formalin, paraffin embedded, serially cross-sectioned at 6 mm, and then stained with
hemotoxylin and eosin. Inflammatory foci represent a minimum of 20 mononuclear cells per perivascular cluster.2044 A Dual-modal Approach to Calm Autoreactive T Cells
splenic APCs rather than TCC-PLP1-1B10. In fact, this
statement is confirmed by the observation that IL-10 was
undetectable when APCs, pulsed with agg Ig-PLP1, were
washed and fixed with paraformaldehyde before incubation
with TCC-PLP1-1B10 (Fig. 6). The other striking obser-
vation from the T cell cytokine assessment assay was that
the production of IFN-g seemed to be decreased as IL-10
production by APCs increased (Fig. 5, c and e). To investi-
gate this issue further, an extended range of Ig-PLP1 con-
centrations was used for stimulation of bulk and purified
APCs, and IL-10 and IFN-g production was assessed si-
multaneously from the same tissue culture well. The results
presented in Fig. 7 clearly indicate that the IL-10 secreted
by the APCs antagonizes the production of IFN-g by the
T cells. Indeed, when the stimulation assay was performed
using splenocytes, purified DCs, or enriched peritoneal
macrophages as APCs (all of which produce IL-10 upon
incubation with agg Ig-PLP1) (Fig. 4), IFN-g production
by the T cells decreased dramatically and became undetect-
able as the production of IL-10 by APCs increased (Fig. 7,
a–c). However, when B cells were used as APCs, which do
not produce IL-10 upon incubation with agg Ig-PLP1 (Fig.
4 b), the secretion of IFN-g by T cells was not affected
(Fig. 7 d). Overall, these results indicate that agg Ig-PLP1
triggers IL-10 production by presenting APCs (DC and
macrophage), and that IL-10 antagonizes the production of
IFN-g by the T cells.
Synergy between Endogenous IL-10 and Peripheral Tolerance
for In Vivo Modulation of Aggressive T Cells. Systemic anti-
gen given to animals without adjuvant usually drives toler-
ance operating through antigen presentation by peripheral
APCs expressing minimal or no costimulatory molecules
(3, 22, 23). Incubation of purified macrophages or DCs
with sol or agg Ig-PLP1, which allows for efficient loading
of peptide onto MHC class II molecules, does not lead to
upregulation of B7-1, B7-2, or CD40 (data not shown).
Furthermore, as agg Ig-PLP1 causes the production of IL-
10 by APCs (Fig. 4), it is likely that IL-10, as has previously
been shown (53, 54), inhibits upregulation of costimulatory
molecules on APCs.
Figure 4. Agg Ig-PLP chimeras induce the production of IL-10 by
APCs. (a) Irradiated (3,000 rads) SJL/J splenocytes (5 3 105 cells/well)
were incubated with graded amounts of sol Ig-PLP1, agg Ig-PLP1, agg
Ig-W, sol Ig-PLP2, or agg Ig-PLP2 for 24 h, and the supernatant was
used to quantitate IL-10 production by ELISA. (b) Irradiated (3,000 rads)
B cells (2 3 105 cells/well), macrophages (0.2 3 105 cells/well), and DCs
(0.2 3 105 cells/well) were incubated with graded amounts of agg Ig-
PLP1 (open symbols) or mouse IgM (filled symbols) for 24 h, and cell
culture supernatant was used to measure IL-10 production. Each point
represents the mean of triplicate wells. These data are representative of
four independent experiments.
Figure 5. Specificity and cytokine response of a Th0 T cell clone to
agg Ig-PLP1. (a) The specificity of the TCC-PLP1-1B10 T cell clone.
SJL/J splenocytes (10.0 3 105 cells/well) were pulsed for 4 h with graded
amounts of free PLP1, free PLP2, agg Ig-PLP1, or agg Ig-PLP2, and then
fixed with paraformaldehyde as described in Materials and Methods. Sub-
sequently, TCC-PLP1-1B10 cells (0.5 3 105 cells/well) were added to
the wells, and proliferation was assessed by [3H]thymidine incorporation.
(b–e) The pattern of cytokine production by TCC-PLP1-1B10 cells
upon stimulation with PLP1 versus agg Ig-PLP1. Irradiated (3,000 rads)
SJL/J splenocytes (5 3 105 cells/well) were incubated with graded
amounts of PLP1 peptide (d) or agg Ig-PLP1 (s) for 1 h, after which
TCC-PLP1-1B10 cells (0.5 3 105 cells/well) were added and the incuba-
tion continued for an additional 24 h. Cytokine production was measured
by ELISA from 100 ml of culture supernatant. Each point represents the
mean of triplicate wells.2045 Legge et al.
As IL-10 has been defined to antagonize Th1 cytokines
(55) and possibly interfere with inflammatory functions, we
postulated that the effectiveness of agg Ig-PLP1 in T cell
modulation and reversal of disease lies on inadequate pep-
tide presentation by APCs expressing minimal costimula-
tory molecules and the inhibitory function of IL-10 pro-
duced by such APCs. To test this hypothesis, mice were
induced for EAE with PLP1 peptide, and when the signs of
paralysis became apparent, the mice were given agg Ig-
PLP1 together with anti–IL-10 antibody and assessed for
reduction in disease severity. The results presented in Fig. 8
a indicate that the severity of paralysis was restored when in
vivo IL-10 was neutralized by the anti–IL-10 antibody. In
fact, mice treated with agg Ig-PLP1 alone had a mean max-
imal clinical score of 1.1 6 0.5, whereas the mice injected
with both agg Ig-PLP1 and anti–IL-10 antibody had a
score of 3.0 6 0.3, which is comparable to the 3.3 6 0.3
(P . 0.23) score seen in mice treated with agg Ig-W. Fur-
thermore, control mice given agg Ig-PLP1 together with rat
IgG, instead of anti–IL-10 antibody, did not restore disease
severity and had a mean maximal score of 1.6 6 0.2. Injec-
tion of anti–IL-10 antibody together with agg Ig-W nei-
ther reduced nor exacerbated the severity of disease. These
results indicate that agg Ig-PLP1–induced IL-10 plays a sig-
nificant role in controlling disease severity, and that for the
effects of IL-10 to occur, a specific interaction between
APCs and the target T cells is required. In support of this
statement is the observation that treatment with sol Ig-
PLP1 plus exogenous IL-10 reduces the severity of paralysis
to the same extent as agg Ig-PLP1 (Fig. 8 b). Sol Ig-PLP1,
which does not induce detectable levels of IL-10, amelio-
rates the disease slightly with a mean maximal score of
2.5 6 0.3, whereas sol Ig-PLP1 together with exogenous
IL-10 further reduces the disease to a mean maximal clini-
cal score of 1.1 6 0.3, which is comparable to the 1.1 6
0.5 score obtained with mice treated with agg Ig-PLP1.
Furthermore, for endogenous IL-10 to modulate the dis-
ease, a physical bridging of the APCs to the T cells seems to
be required. This conclusion is drawn from the observation
that treatment of diseased mice with a mixture of agg Ig-W
and free PLP1 peptide, instead of agg Ig-PLP1, did not re-
duce the severity of disease (Fig. 9). Overall, effective T
cell downregulation requires physical interaction between
IL-10–producing APCs and the target pathogenic T cell.
The likely explanation for this requirement is that IL-10 as
a paracrine cytokine needs to be in close proximity to T
cells in order to achieve antagonism.
Treatment with Aggregated Ig-PLP1 Decreases the Clinical
Severity of Active EAE Induced by Multiple Epitopes. IL-10
produced by APCs as a result of agg Ig-PLP1–mediated
FcR cross-linking may antagonize specific T cells engaged
to the PLP1–MHC ligand on the APCs as well as neigh-
boring T cells with unrelated specificity. This phenome-
non, known as bystander suppression, has proven effective
in IL-4 (56) and IL-10 (57) settings. One way to find out if
bystander suppression could be ascribed to the IL-10 in our
experimental system is to induce EAE with a mixture of
epitopes and test if treatment with agg Ig-PLP1 could
Figure 6. Agg Ig-PLP1 does
not induce IL-10 production by
the TCC-PLP1-1B10 T cell
clone. Fixed and live APCs were
used to identify the source of IL-
10 in T cell activation by agg Ig-
PLP1. In the fixed APC assay,
SJL/J splenocytes (10 3 105
cells/well) were pulsed with
graded amounts of agg Ig-PLP1
for 4 h, washed extensively, and
fixed with paraformaldehyde. In
the live APC assay, irradiated
(3,000 rads) SJL/J splenocytes
(5  3 105 cells/well) were mixed
with graded amounts of agg Ig-
PLP1 and incubated for 1 h.
Subsequently, TCC-PLP1-1B10 cells (0.5 3 105 cells/well) were added
to both assays and the incubation continued for an additional 24 h. IL-10
production was measured by ELISA from 100 ml of culture supernatant.
Each point represents the mean of triplicate wells.
Figure 7. APCs’ IL-10 induced by agg Ig-PLP1 antagonizes IFN-g
production by T cells. Irradiated (3,000 rads) SJL/J splenocytes (5 3 105
cells/well), DCs (0.2 3 105 cells/well), macrophages (0.2 3 105 cells/
well), or B cells (2 3 105 cells/well) were incubated with graded amounts
of agg Ig-PLP1, and after 1 h TCC-PLP1-1B10 cells (0.5 3 105 cells/
well) were added and the incubation continued for an additional 24 h.
IFN-g and IL-10 production in the same culture well was measured by
ELISA. Each point represents the mean of triplicate wells.2046 A Dual-modal Approach to Calm Autoreactive T Cells
modulate unrelated autoreactive T cells and ameliorate the
disease. This experiment was carried out, and the results
presented in Fig. 10 a show that mice with ongoing EAE
induced by a mixture of PLP1 and PLP2 peptides mani-
fested reduced severity of paralysis and fully recovered by
day 33 after disease induction upon treatment with agg Ig-
PLP1, whereas animals treated with agg Ig-W had severe
paralysis and did not recover from the disease during the
50-d period of clinical assessment. Therefore, endogenous
IL-10 may have displayed downregulatory effects on PLP2-
specific T cells. Induction of disease with PLP2 peptide
should expose whole PLP and drive spreading and activa-
tion of PLP1-specific T cells (17, 58). In this case, injection
of agg Ig-PLP1 should bridge IL-10–producing APCs to
PLP1-specific T cells and promote bystander suppression of
these cells as well as neighboring PLP2-specific T cells. To
address this issue, mice were induced for EAE with PLP2
peptide, and when signs of paralysis became apparent, they
were treated with agg Ig-PLP1. Fig. 10 b shows that al-
though the initial phase of paralysis in these mice is only
slightly milder than untreated mice, the animals quickly re-
covered by day 26, and unlike the untreated mice, did not
relapse for the remaining period of clinical assessment.
These results strengthen the notion of bystander suppres-
sion and suggest that epitope spreading offers an opportu-
nity to modulate disease at a later stage of paralysis.
To further explore the broadness of this approach in T
cell downregulation, we tested agg Ig-PLP1 for modula-
Figure 8. Neutralization of Ig-PLP1–induced endogenous IL-10 re-
stores severity of paralysis. (a) SJL/J mice (eight per group) were induced
for EAE with 100 mg PLP1, and on days 9, 13, and 17 were given intra-
peritoneally in PBS 300 mg agg Ig-PLP1 (agg Ig-PLP1); 300 mg agg Ig-
PLP1 plus 500 mg rat anti–mouse IL-10 antibody, 2A5 (agg Ig-PLP1 1
anti-IL-10); 300 mg agg Ig-PLP1 plus 500 mg rat IgG (agg Ig-PLP1 1 rat
IgG); 300 mg agg Ig-W (agg Ig-W); or 300 mg agg Ig-W plus 500 mg rat
anti–mouse IL-10 antibody, 2A5 (agg Ig-W 1 anti-IL-10). All the injec-
tions were done intraperitoneally in PBS. (b) Exogenous IL-10 synergizes
with sol Ig-PLP1 to reduce the severity of EAE. Groups of mice (eight per
group) were induced for EAE with 100 mg PLP1 and on days 9, 13, and
17 were given intraperitoneally in PBS 300 mg sol Ig-PLP1 (sol Ig-PLP1);
300 mg agg Ig-PLP1 (agg Ig-PLP1); 300 mg sol Ig-PLP1 plus 400 U re-
combinant IL-10 (sol Ig-PLP1 1 IL-10); or 300 mg agg Ig-W (agg Ig-W).
Figure 9. Requirement for a physical linkage of the Ig vehicle to PLP1
peptide for amelioration of EAE. Groups of mice (eight per group) were
induced for EAE with 100 mg PLP1, and then treated with 300 mg of agg
Ig-PLP1 (agg Ig-PLP1), 300 mg agg Ig-W (agg Ig-W), or 300 mg agg Ig-W
plus 100 mg PLP1 (agg Ig-W 1 PLP1) in PBS on days 9, 13, and 17 after
disease induction. The onset of disease was at day 7 in these experimental
groups.
Figure 10. Aggregated Ig-PLP1 modulates disease involving intramo-
lecular epitopes. (a) Groups of SJL/J mice (eight per group) were induced
for EAE with a mixture of 100 mg PLP1 and 100 mg PLP2 and on days 9,
13, and 17 treated with 300 mg agg Ig-PLP1 or agg Ig-W per injection.
All treatments were intraperitoneally in PBS. The onset of disease was at
day 7 in these experimental groups. Each point represents the mean clini-
cal score of eight mice. (b) Groups of SJL/J mice (eight per group) were
induced for EAE with 100 mg PLP2 and on days 9, 13, and 17 treated in-
traperitoneally with 300 mg agg Ig-PLP1 per injection. A group of un-
treated mice (NIL) was included for comparison purposes.2047 Legge et al.
tion of disease induced with CNS homogenate, which in-
corporates a full range of myelin autoantigens. The results
presented in Fig. 11 clearly indicate that mice injected with
agg Ig-PLP1 had mild signs of paralysis in the initial phase
of paralysis and fully recovered by day 24 after disease in-
duction without any relapses for the 60-d period of clinical
assessment. Control mice treated with agg Ig-W instead of
agg Ig-PLP1 had a disease pattern similar to that of un-
treated animals (Fig. 11). These results indicate that the
downregulatory function of agg Ig-PLP1 extends to both
intra- and intermolecular epitopes and suppresses diverse T
cell specificities.
Exposure to IL-10 seems to be the likely mechanism un-
derlying downregulation and suppression of pathogenic
myelin-specific T cells. The source of IL-10, as demon-
strated in Figs. 4 and 6, is APCs such as DCs and macro-
phages. However, the broadened effectiveness and the
endurance of T cell modulation in this setting raise the
question of whether the bystander suppression was due to
antagonism of the pathogenic T cells by APCs’ IL-10, or to
downregulation by regulatory T cells generated under the
effect of such IL-10 (59). The rationale for this statement
derives from previous studies suggesting that IL-10 enables
naive T cells to develop into regulatory cells (59) that could
produce IL-10, IL-5, or TGF-b and inhibit the function of
pathogenic T cells, thereby sustaining suppression (46, 60–
63). To address this issue, the LN T cells from mice that
were recovering from CNS-induced paralysis subsequent
to treatment with agg Ig-PLP1 were stimulated with anti-
gen and tested for proliferation and production of cytokines
markers of regulatory T cells. The results presented in Fig.
12 show that 2 d after the final injection of agg Ig chimeras,
proliferation to myelin peptides was significant in the mice
treated with the control Ig-W but at background levels for
those recipient of agg Ig-PLP1. Similarly, while the mice
injected with agg Ig-W had significant amounts of IL-2 and
IFN-g, those treated with agg Ig-PLP1 had neither Th1-
nor Th2-type cytokines and did not produce IL-10, IL-5,
or TGF-b. Similar results were obtained when the mice
were tested at day 9 after completion of the treatment regi-
men (data not shown). Furthermore, splenic T cells and
cells harvested from the peritoneum showed a similar pat-
tern of responses (data not shown). Overall, these results
suggest that the typical proliferative and cytokine responses
trademark of regulatory T cells are undetectable in this par-
ticular setting of systemic treatment of active autoimmu-
nity.
Figure 11. Agg Ig-PLP1 modulates disease involving intra- and inter-
molecular epitopes. Groups of SJL/J mice (nine per group) were induced
for EAE with 6 mg of CNS homogenate and on days 9, 13, and 17 treated
intraperitoneally with 300 mg agg Ig-PLP1 or agg Ig-W per injection. A
group of untreated mice (NIL) was included for comparison purposes.
Figure 12. Treatment of CNS homogenate–induced EAE with aggre-
gated Ig-PLP1 suppresses proliferative and cytokine responses to diverse
myelin epitopes. Mice (six per group) were induced for EAE with CNS
homogenate and then treated with agg Ig-W (hatched bars) or agg Ig-
PLP1 (black bars) on days 9, 13, and 17 as described in the legend to Fig.
11. 2 d after completion of the treatment regimen, the LNs (axillary, lat-
eral axillary, and popliteal) were harvested, and the cells (4 3 105 cells/
100 ml/well) were stimulated with 100 ml/well of antigen. (a) Cell prolif-
eration was assessed 3 d later using [3H]thymidine incorporation assay.
(b–g) Cytokine responses were analyzed after 24 h of incubation with an-
tigen by enzyme-linked immunospot (ELISPOT) assay using 5 3 105
cells per well. The antigens were used at the defined optimal concentra-
tions of 15 mg/ml for PLP1, PLP2, and HA and 30 mg/ml for MBP-3.
Control wells of media without addition of antigen were included and
used as background. Each bar represents the mean 6 SD of six individu-
ally tested mice. Similar results were observed when the in vitro stimula-
tors were used with two times higher concentrations. Also, the pattern of
proliferation and cytokine production was similar when the splenic and
peritoneal cells from these animals were analyzed.2048 A Dual-modal Approach to Calm Autoreactive T Cells
Discussion
Previous studies have demonstrated that delivery of pep-
tides on Igs increases presentation to T cells in vitro by
100–1,000-fold relative to free peptide (30, 31) and induces
stronger T cell responses in vivo (31, 64). Internalization of
Ig-peptide chimeras into APCs via FcRs and access of the
attached peptide to newly synthesized MHC class II mole-
cules are most likely responsible for such effective presenta-
tion (31, 50). The efficacy of peptide delivery by Igs seems
to extend to peripheral APCs expressing minimal or no co-
stimulatory molecules, as injection of the Ig-PLP1 chimera
without adjuvant into diseased mice modulates PLP1-spe-
cific pathogenic T cells and ameliorates EAE (Fig. 1). This
statement is supported by the finding that 200 nmol of
PLP1 in the form of free peptide reduced the severity of
disease only slightly and the animals never recovered, but
20 nmol of peptide in the form of sol Ig-PLP1 reduced the
severity of the initial phase of disease and most of the ani-
mals fully recovered by day 42 (Fig. 1). The effectiveness of
Ig-PLP1 in disease reversal was more dramatic when the
chimera was given to mice in an aggregated form (Figs. 2
and 3, and Table I). The explanation we wish to put forth
for this observation is that agg Ig-PLP1 displays an antago-
nistic function against T cells at two levels. On the one
hand, as Ig-PLP1 was injected without any adjuvant it is
likely that presentation was carried out mostly by periph-
eral APCs not expressing optimal costimulatory molecules,
thereby leading to inactivation of the T cells. In fact, incu-
bation of purified DCs and macrophages with sol or agg Ig-
PLP1 did not induce upregulation of B7 or CD40 costimu-
latory molecules. On the other hand, the presenting APCs
produce IL-10, which further antagonizes the T cells en-
gaged to them through PLP1 peptide. The evidence for
this dual-modal mechanism for T cell turn off derives from
two essential observations. First, soluble adjuvant-free Ig-
PLP1, which does not induce detectable levels of IL-10
(Fig. 4 a), modulates the disease with significantly fewer
copies of peptide than free PLP1 peptide (Fig. 1). Second,
agg Ig-PLP1, which induces IL-10 production by mac-
rophages and DCs (Fig. 4 b), enhances T cell antagonism,
as the mice display a significant reduction in the frequency
and size of inflammatory foci both in the brain and spinal
cord (Fig. 3, and Table I), manifest very mild clinical signs
of EAE, and fully recover from paralysis by day 25 after dis-
ease induction (Fig. 2). The contribution of IL-10 to T cell
modulation and disease amelioration is supported by both
in vitro and in vivo data. Indeed, the TCC-PLP1-1B10 T
cell clone, which proliferates and produces both type I and
II cytokines upon incubation with free PLP1 (Fig. 5), sig-
nificantly reduced IFN-g production when agg Ig-PLP1
was used for stimulation (Fig. 5). This is well illustrated in
Fig. 7, which shows that the production of IFN-g by T
cells is inversely proportional to the IL-10 production by
DCs and macrophages within the same cell culture. In
vivo, neutralization of APCs’ IL-10 by anti–IL-10 antibod-
ies during treatment with agg Ig-PLP1 restores the severity
of disease to scores comparable with Ig-W treatment (Fig.
8 a). Furthermore, the combination of recombinant IL-10
and sol Ig-PLP1 reduces disease severity to the same extent
as agg Ig-PLP1 (Fig. 8 b). All together, these results suggest
that effective control of EAE requires synergy of antagonis-
tic functions against T cells, and points out the need for a
multimodal strategy to contain autoimmunity. In fact, sys-
temic injection of IL-10 has proven inefficient for modula-
tion of autoimmunity (65), and only overexpression of
IL-10 by means of transgenic manipulation (66), targeted
delivery of the cytokine by means of engineered T cells (27),
or viral gene transfer (29) has proven effective for control
of T cell–mediated autoimmunity. The agg Ig-peptide ap-
proach brings together a peripheral tolerance-like mecha-
nism and the antagonism activity of IL-10 to strengthen the
modulatory functions against aggressive T cells. Further-
more, as IL-10 exerts its downregulatory function in a
paracrine fashion, it may counteract neighboring Th1 cells
regardless of antigen specificity. This behavior, known as
bystander suppression (56, 57), seems to contribute to dis-
ease modulation by agg Ig-PLP1. Indeed, mice induced for
EAE with a mixture of PLP1 and PLP2 peptides recovered
from paralysis when they were treated with agg Ig-PLP1
(Fig. 10). The likely explanation for these results is that IL-
10 produced by the APCs exerts an antagonist effect on
neighboring T cells specific for PLP2 peptide, thereby
modulating disease involving two epitopes. Moreover,
when the disease was initiated with PLP2 peptide, the
treatment with agg Ig-PLP1 allowed paralysis to peak to a
significant clinical score but the recovery was expeditious
and relapses did not occur. This pattern could suggest that
IL-10–mediated bystander suppression had to await expo-
sure of PLP and generation of PLP1-specific T cells to fo-
cus the presenting APCs and their IL-10 on the pathogenic
T cells. This has twofold importance for the usefulness of
this approach for treatment of autoimmunity. First, using
this strategy for intervention at the initial phase of disease
will likely modulate paralysis, as the target T cells should
become available to focus the APCs and their IL-10 on
neighboring pathogenic T cells regardless of their specific-
ity. Second, as epitope spreading seems to follow a sequen-
tial order and sustain specific relapses (58), one could devise
a regimen to target T cell modulation at later phases in the
relapses. The data presented in Fig. 11, showing that agg
Ig-PLP1 modulates disease induced with CNS homoge-
nate, argue for the broad effectiveness of the approach and
support the notion that bystander suppression offers a strat-
egy for intervention at various stages of the disease.
At the mechanistic level, the in vitro data demonstrate
that while IL-10 downregulates the Th1 type cytokine
IFN-g, produced by the TCC-PLP1-1B10 Th0 clone,
production of the Th2 cytokine IL-4 was not affected (Fig.
5). This suggests that IL-10 antagonism partially affects the
specific functions of the T cell rather than driving full inac-
tivation or death of the cells. Whether IL-10 exerts a simi-
lar activity on differentiated Th1 cells in vivo remains to be
investigated. On a speculative basis, if IL-10 affects IL-122049 Legge et al.
synthesis by the APCs, a complex regulatory mechanism
could be triggered around T cell–APC interactions possibly
via CD40–CD40L, resulting in downregulation of Th1
function and suppression of IFN-g production (67–69).
On the other hand, one could speculate that APCs’ IL-
10 may promote the development of regulatory T cells (46,
59–63), which in turn would help in downregulation of
the pathogenic T cells. In fact, this would provide a good
argument for the broad and sustainable bystander suppres-
sion, as regulatory T cells could produce suppressive cyto-
kines such as IL-10 and TGF-b (61, 63). However, the re-
sults presented in Fig. 12 provided no support for this
speculation and neither proliferation nor IL-10, IL-5, or
TGF-b were obtained subsequent to treatment with agg
Ig-PLP1. Although high concentrations of peptide were
used for in vitro stimulation and cells from various tissues
have been assayed for production of IL-10, IL-5, and TGF-b,
this does not provide a definitive exclusion of regulatory
cells. A few decades ago, Jerne (70) postulated that the im-
mune system keeps itself in check by sustaining an equilib-
rium of interaction among its components. Pathogenic T
cells could be kept harmless by a tight control from regula-
tory T cells. A perturbation of these interactions would
lead to oscillations in the levels of each component. At the
time of recovery, the regulatory T cells may have returned
to minimal levels below the sensitivity of our assays.
Overall, agg Ig-PLP1 promotes efficient peptide loading
onto MHC molecules and couples a peripheral tolerance-
like mechanism and directed IL-10 bystander suppression
to counteract aggressive T cells and modulate complex au-
toimmunity involving multiple epitopes. One should em-
phasize that the effectiveness of the approach and its by-
stander suppression likely lies on the physical link of the Ig
vehicle to the peptide, which serves to bridge the APCs to
the T cell and focus IL-10 on the neighboring pathogenic
lymphocytes. This dual-modal approach, which proves to
be efficient in this autoimmune setting where a high pre-
cursor frequency probably entertains the severe paralysis
(71), may prove feasible for treatment of human multiple
sclerosis, which likely involves several myelin autoantigens
(19, 72).
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